Status:
COMPLETED
Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation
Lead Sponsor:
Columbia University
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Heart Transplantation
Liver Transplantation
Eligibility:
All Genders
20-70 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to compare the effectiveness and safety of zoledronic acid with alendronate in the prevention of bone loss after organ transplantation. Zoledronic acid is given as a singl...
Detailed Description
Patients who have undergone heart or liver transplantation are usually required to remain on medications, such as Prednisone and Cyclosporine A or Tacrolimus, that prevent the body from rejecting the ...
Eligibility Criteria
Inclusion
- A man or woman, aged 20 to 70, of any race who has had a heart or liver transplant
Exclusion
- hyperparathyroidism
- Paget's disease
- hyperthyroidism
- cancer
- severe kidney disease,
- intestinal disease
- active peptic ulcer disease
- current or past treatment for osteoporosis
- pregnancy or lactation
- severe oral/dental disease
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT00297830
Start Date
November 1 2005
End Date
January 1 2014
Last Update
August 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Medical Center
New York, New York, United States, 10032